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Background: Increased ratio of n-3/n-6 polyunsaturated fatty acids (PUFAs) in diet or serum may have a protective
effect on the risk of breast cancer (BC); however, the conclusions from prospective studies are still controversial. The
purpose of this study is to ascertain the relationship between intake ratio of n-3/n-6 PUFAs and the risk of BC, and
estimate the potential summarized dose–response trend.
Methods: Relevant English-language studies were identified through Cochrane Library, PubMed and EMBASE database
till April 2013. Eligible prospective studies reporting the multivariate adjusted risk ratios (RRs) for association of n-3/n-6
PUFAs ratio in diet or serum with BC risk. Data extraction was conducted independently by 2 investigators; disagreements
were reconciled by consensus. Study quality was assessed using the Newcastle-Ottawa scale. Study-specific RRs were
combined via a random-effects model.
Results: Six prospective nested case–control and 5 cohort studies, involving 8,331 BC events from 274,135 adult
females across different countries, were included in present study. Subjects with higher dietary intake ratio of n-3/n-6
PUFAs have a significantly lower risk of BC among study populations (pooled RR = 0.90; 95% CI: 0.82, 0.99), and per
1/10 increment of ratio in diet was associated with a 6% reduction of BC risk (pooled RR = 0.94; 95% CI: 0.90, 0.99;
P for linear trend = 0.012). USA subjects with higher ratio of n-3/n-6 in serum phospholipids (PL) have a significantly
lower risk of BC (pooled RR = 0.62; 95% CI: 0.39, 0.97; I2 = 0.00%; P for metaregression = 0.103; P for a permutation
test = 0.100), and per 1/10 increment of ratio in serum PL was associated with 27% reduction of BC risk (pooled
RR = 0.73; 95% CI: 0.59, 0.91; P for linear trend = 0.004; P for metaregression = 0.082; P for a permutation test = 0.116).
Conclusions: Higher intake ratio of n-3/n-6 PUFAs is associated with lower risk of BC among females, which implies
an important evidence for BC prevention and treatment is by increasing dietary intake ratio of n-3/n-6 PUFA. No firm
conclusions from USA populations could be obtained, due to the limited numbers of USA studies.Background
Although breast cancer (BC) is the most common can-
cer occurring among women worldwide, international
variation of BC incidence show there is a higher inci-
dence in North America and Western Europe, but lower
incidence in Asia [1,2]. The large geographic hetero-
geneity of incidence among women globally could be ex-
plained by variation of dietary patterns, especially with* Correspondence: duoli@zju.edu.cn
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unless otherwise stated.relation to dietary fat as a potential dietary factor that is
closely correlated with increased incidence of BC [3-6].
Polyunsaturated fatty acids (PUFAs) as dietary fat sub-
types consist of two families: n-3 PUFAs and n-6 PUFAs.
Serum phospholipids (PL) ratio of n-3/n-6 PUFA can
directly reflect dietary intake ratio of n-3/n-6 PUFA, due
to the lack of interconversion between n-3 and n-6
PUFAs in humans. N-3 and n-6 PUFAs in vivo can influ-
ence breast tumor cell growth by simultaneously com-
peting for the same metabolic pathway (COX and LOX
pathway) to change the balance of tissue eicosanoids,
the transcription mediated by nuclear factor κB (NF-κB),
and signal transduction mediated by the mammalian tar-
get of rapamycin (mTOR) etc. [7-9]. Therefore, ratio ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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important role in the risk of BC.
The studies from cell lines and animals have shown
promising results of down regulating BC tumor growth
by n-3 PUFAs as a nutrient to compete with n-6 PUFAs
[10,11]. Most of the case–control studies also support
that dietary or serum PL n-3/n-6 ratio is inversely asso-
ciated with risk of BC [4,5,12-14]. However, there are
some inconsistent conclusions in prospective studies
[15-20], and the optimal intake ratio of n-3/n-6 PUFAs
has not yet been well defined. Therefore, it is necessary
to quantitatively ascertain the association between intake
ratio of n-3/n-6 PUFAs and the risk of BC by means of
meta-analysis. Available data from prospective studies
of adult females (premenopausal, postmenopausal, or
combined) across different countries were pooled to
summarize the relationship between intake ratio of n-3/
n-6 PUFAs and the risk of BC for highest vs. lowest
quantile, to estimate the potential dose–response trend
and to conduct the stratified analysis for exploring the
probable source of heterogeneity.
Methods
Literature search
We identified prospective studies which reported the asso-
ciation between intake ratio of n-3/n-6 (n-6/n-3) and
BC risk up until April 2013 from PubMed, Embase,
and Cochrane Library database using literature retrieval
of subject headings. Search strategy was (“Fatty Acids,
Omega-3″ OR “Fatty Acids, Omega-6″) AND “Breast
Neoplasms” for PubMed, “Breast tumor” AND (“omega
3 fatty acid” OR “omega 6 fatty acid”) for EMBASE and
“Fatty Acids” AND “Breast Neoplasms” for Cochrane
Library databases. We also searched systematic reviews
from the above-mentioned database, and checked re-
ference lists to identify studies that might have been
missed. The present meta-analysis was conducted using
the standard methods from Cochrane Collaboration,
and reporting items were mainly based on MOOSE
guidelines for meta-analysis of observational studies [21]
(Additional file 1). Ethical approval and informed
consent were not required for this meta-analysis.
Eligibility criteria
1) Participants: study population included any adult
women (premenopausal, postmenopausal, or combined),
whose base conditions were regarded as stable; 2) Ex-
posure: evaluating ratio of n-3/n-6 (n-6/n-3) PUFAs in
diet or human serum (plasma) PL; 3) Outcomes: evalua-
ting BC incidence as outcome variable and providing
risk ratios (RRs) for all categories of dietary or serum
(plasma) PL ratio of n-3/n-6 or n-6/n-3 PUFAs; 4) Study
Design: prospective studies (cohort, nested case–control
and case-cohort study) were included.Study identification
Two trained investigators (YF and JG) identified articles
eligible for further review by performing a stepwise
screening of titles or abstracts, followed by a full-text re-
view based on common inclusion criterion. Discre-
pancies were resolved through discussion with the third
investigator (BY). Studies of cross-sectional, cross-over,
randomized controlled trials (RCT), experimental designs
(cell culture and animal test), non- original research
(reviews, editorials, or commentaries), abstract, un-
published studies, or duplicated studies were excluded.
Our search was restricted to human studies published in
English. We did not contact authors for the detailed infor-
mation of primary studies only reporting association of
n-3 or n-6 PUFA with BC risk. We contacted the authors
of the two studies reporting association of n-3 and
n-6 PUFA with BC risk by email.
Data extraction and quality assessment
Data extraction was finished independently and per-
formed twice by two reviewers (YF and JG), and dis-
agreements were reconciled by consensus. Detailed data
concerning participants, exposure, comparability and
outcomes were extracted using a standard extraction
form (Additional file 2). We mainly aimed to extract
the characteristics of participants (e.g., nationality, age,
menopausal status, follow-up duration and number
of participants), intake n-3/n-6 (n-6/n-3) ratio exposure
(e.g., measurement method, exposure source, and expo-
sure range), covariates adjusted in multivariable analysis
and RRs including corresponding confidence intervals
(CIs) for all categories of dietary or serum (plasma) PL
ratio of n-3/n-6 (n-6/n-3) PUFAs. Quality assessment
was performed by using the Newcastle-Ottawa scale
(NOS) [22], which mainly contains selection domain
(0–4 stars), comparability domain (0–2 stars) and expo-
sure or outcomes domain (0–3 stars).
Data synthesis and statistic analysis
In this meta-analysis, intake ratio of n-3/n-6 PUFAs was
defined as the proportion of total n-3 PUFAs (the sum
of ALA, EPA and DHA) to total n-6 PUFAs in diet
or serum (plasma) PL, and pooled RR including corre-
sponding 95% CI was taken as the summary risk esti-
mate for all studies. RRs from each study were firstly
transformed to their logarithm (logRR), and correspond-
ing 95% CIs were used to calculate corresponding
standard errors (selogRR). We conducted two types of
meta-analysis. Firstly, we conducted meta-analysis for
the highest quantile (tertile, quartile and quintile)
compared with lowest or reference, and study-specific
RRs were combined using a random-effects model
described by DerSimonian and Laird [23], which con-
siders both within-study and between-study variability.
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performed using the method described by Greenland and
Orsini, et al. [24,25] to estimate the potential linear trend
and achieve association between per 1/10 increment of
intake ratio of n-3/n-6 PUFAs and BC risk (Additional
file 3). To examine a potential nonlinear (curvilinear)
trend, we used the restricted cubic splines functional
model with three knots at percentiles 25%, 50%, and 75%
of the distribution. A p-value for curvilinear trend was cal-
culated by testing the null hypothesis that the coefficient
of the second spline is equal to zero [26,27].
Heterogeneity was assessed with the Q test and I2 stat-
istic. We considered an I2 value greater than 50% and
2-tailed P < 0.10 as indicative of heterogeneity according
to Cochrane Handbook, and defined the low, moderate
and high degrees of heterogeneity by I2 values of 25%,
50% and 75% as cut-off points [28] respectively. If het-
erogeneity was presented in this meta-analysis, meta-
regression and subgroup analyses were conducted to
identify the potential sources of heterogeneity by study
design (cohort study and nested case–control study), dif-
ferent regions (Europe, USA and Asia), menopausal
status (pre-, post- and combined), and follow-up du-
ration (more than and less than average value) and
known covariates adjusted (e.g., BMI, age, and family
history of BC) in multivariate analysis.
Sensitivity analysis was performed to evaluate potential
influence of individual study on overall risk estimation,
and compare the pooled RR from random effect modelFigure 1 PRISMA flow diagram for included prospective studies.with that from fixed effect model. Potential publication
bias was qualitatively delineated by the asymmetry of
funnel plot, and it was also quantitatively examined by
Begg’s test and Egger’s regression test (P < 0.05 was
considered representative of statistical significance) [29].
If potential publication bias was found in the meta-
analyses, contour-enhanced funnel plot was performed
to explore the probable source of publication bias [30].
This method examined the visual asymmetry of funnel
plot, and differentiated asymmetry due to publication
bias from other factors [31]. Statistical analysis of the
combined data was performed by STATA version 11.0
(Stata CORP, College Station, TX).
Results
We identified 1,112 potential studies from electronic
search, and 772 studies were left after removing dupli-
cates. Thirty one prospective studies were obtained after
title and abstract review. Eleven studies were eligible
for inclusion in the present study after full text review
(Figure 1), and 20 studies were excluded for other rea-
sons (Additional file 3).
Characteristics of the included studies
Included studies consist of 5 prospective cohort studies
[15-17,32,33] and 6 prospective nested case–control stu-
dies [18-20,34-36] (Table 1; Additional file 1). The 6 stu-
dies looked at intake of dietary fatty acid [15-17,32,33,35],
which was quantified by food frequency questionnaires
Table 1 Characteristics of included prospective studies







qualityMeasurement Range (H vs. L)a
Vatten 1993 [18] (Norway) NCC Subjects from serum bank; 87/235; Pre- 5 n-3/n-6: Serum
PL, GC (mg/L)




Chajes 1999 [35] (Sweden) NCC Cardiovascular disease
Cohort; 196/388;
Combined 2 ~ 11 LC n-3/n-6: Serum
PL, GC (%tFC)




Saadatian-Elahi 2002 [19] (USA) NCC Health university Women
cohort; 197/197;
Pre- and Post- 4.3 n-3/n-6: Serum
PL, GC (%tFC)







Wirfalt 2002 [36] (Sweden) NCC Malmo Diet and Cancer
(MDC) Cohort; 237/673;
Post- 3 ~ 8 n-3/n-6: Diet,
FFQ (g/day)




Wakai 2005 [17] (Japan) PC Japan Collaborative Cohort
Study (JACC);129/26291









☆☆☆Post-: > 4.59 vs. < 3.21 Post-: 1.30
(0.66, 2.58)
Chajes 2008 [20] (Sweden) NCC Europe Prospective Investigation
into Cancer and Nutrition
(EPIC); 363/702;
Combined. 7.0 n-6/n-3: Serum
PL, GC (%tFC)




Takata 2009 [37] (USA) NCC Beta Carotene and Retinol
Efficacy Trial chort study
(CARET); 103/309;
Post-. 4.4 n-3/n-6: Serum
PL, GC (%tFC)




















Table 1 Characteristics of included prospective studies (Continued)
Thiebaut 2009 [33] (France) PC EPIC Cohort; 1650/56007 Combined 8.0 n-6/n-3:Diet,
FFQ, (% energy)




Murff 2011 [16] (China) PC Shanghai Women Health
Study cohort (SWHS); 712/72571;
Combined 8.0 n-6/n-3: Diet,
FFQ, (g/day)




Park 2012 [15] (USA) PC Multiethnic Cohort; 3885/85089; Post- 12 n-6/n-3: Diet,
FFQ, (g/1000 kcal)




Sczaniecka 2012 [34] (USA) PC Vitamins and Lifestyle (VITAL)
cohort study; 772/30252;
Post-. 6.0 n-3/n-6: Diet,
FFQ, (g/day)




aH vs. L: the highest exposure quantile vs. lowest or reference.
%tFC = percentage of total Fatty Acid; GC = Gas Chromatography; LC n-3 = long chain n-3 PUFAs including EPA, DPA and DHA; NCC = prospective nested case–control study; PC = prospective cohort study;
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percentage of energy (% energy) [17,32], and grams per
1,000 kilocalorie (g/1000 kcal) [15]. There are 5 studies
concerning serum PL biomarker, where fatty acid compo-
sitions in serum PL was quantified by gas chromatog-
raphy, and measurement unit was percentage of total fatty
acids, except for 1 study (mg/L) [18]. One study provided
data of pre- and post-menopausal women separately
[19], 1 study of pre-menopausal [18], 4 studies of post-
menopausal [15,33,35,36], and 5 studies of combined
women [16,17,30,32,34]. Five studies were reported from
Europe [18,20,32,34,35], 4 studies from USA [15,19,33,36],
and 2 studies from Asia [16,17]. NOS stars of all included
studies ranged from 4 to 10, with an average of 7.55. High
quality studies (NOS stars ≥ 8) accounted for 55% of
all studies [15-17,19,33,36], and moderate quality studies
(6 ≤NOS stars ≤ 7) accounted for 45% of all studies
[18,20,32,34,35].
Highest vs. lowest quantile of ratio of n-3/n-6 PUFAs
We performed a random-effects model meta-analysis for
highest quantile compared with lowest (Figure 2). Eleven
independent prospective studies reported the association
between ratio of n-3/n-6 and risk of breast cancer,
involving 8,331 BC events and 274,135 adult females
(premenopausal, postmenopausal, or combined) across
different countries. Intake ratio of n-3/n-6 PUFA was in-
versely associated with BC risk for the highest vs. lowestFigure 2 Forest plot of ratio of n-3/n-6 PUFAs in diet or serum PL for
serum PL ratio of n-3/n-6 PUFAs separately are referred to by first author, y
according to the inverse of the variance of the logRR estimate. The relative
to the weights used in the meta-analysis), and CIs are represented by the e
for the highest exposure quantile vs. lowest from individual study were po
pooled RR from subtotal risk estimate of dietary or serum PL ratio, accordinquantile among study populations (pooled RR = 0.90;
95% CI: 0.82, 0.99; I2 = 11.40%; Pheterogeneity = 0.33).
Summarized dose–response meta-analysis
We performed summarized dose–response meta-analysis
to determine the potential linear and curvilinear trend.
Four articles reporting PUFA as g/day were eligible for the
dose–response association between dietary ratio and BC
risk [15,16,33,35]. There was statistical significance of
dose–response trend (Plinear = 0.012; Pcurvilinear = 0.018)
among study populations. Per 1/10 increment of dietary
n-3/n-6 ratio was associated with a 6% reduction of BC
risk (pooled RR = 0.94; 95% CI: 0.90, 0.99; I2 = 3.20%,
Pheterogeneity = 0.38) (Figures 3 & 4).
Four articles reporting PUFAs as compositions were
eligible for the dose–response association of serum PL
biomarker with BC risk [15,16,18,19,33-36]. There was
no statistical significance of dose–response trend (Plinear =
0.178; Pcurvilinear = 0.832) among study populations,
and the pooled RR for per 1/10 increment of n-3/n-6 ratio
in serum PL was 0.89 (95% CI: 0.74, 1.06; I2 = 42.00%,
Pheterogeneity = 0.14) (Figure 3). Further stratifying by geo-
graphical regions, there was statistical significance of
dose–response trend among USA populations from 2
studies (Plinear = 0.004; Pcurvilinear = 0.09), and per 1/10
increment of n-3/n-6 ratio in serum PL was associated
with a 27% reduction of BC risk (pooled RR = 0.73;
95% CI: 0.59, 0.91; I2 = 0.00%). There was no statisticalthe highest vs. lowest. Prospective studies concerning dietary and
ear of publication and number of subjects, weighted and ranked
risks (RRs) are represented by the squares (the size is proportional
rror bars. P values for heterogeneity test (I square and Q test) and RR
oled by using random effect model. The diamonds can represent the
g to their corresponding position in the figure.
Figure 3 Forest plot of per 1/10 increment of n-3/n-6 PUFAs ratio in diet and serum PL. Prospective studies eligible for dose–response
analysis are referred to by first author and year of publication. The relative risks (RRs) are represented by the squares (the size is proportional to
the weights used in the meta-analysis), and confidence intervals (CIs) are represented by the error bars. P values and I square for heterogeneity
test were shown by using random effect model. The diamonds can separately represent the pooled RR for association between per 1/10 incre-
ment of dietary or serum PL ratio of n-3/n-6 PUFA and BC risk, which was combined by a two-stage random-effect model. Figure A indicated
association of BC risk with per 1/10 dietary ratio of n-3/n-6 PUFA, whereas Figure B indicated association of BC risk with pre 1/10 serum PL ratio
of n-3/n-6 PUFA.
Yang et al. BMC Cancer 2014, 14:105 Page 7 of 14
http://www.biomedcentral.com/1471-2407/14/105significance of dose–response trend among Europe popu-
lations from 2 studies (Plinear = 0.70; Pcurvilinear = 0.95), and
the pooled RR of per 1/10 increment of ratio in serum
PL was 1.03 (95% CI: 0.88, 1.21; I2 = 0.00%) (Figure 3;
Additional file 3). However, a permutation test from
metaregression did not show significant difference between
the two populations (P for metaregression = 0.086; P for a
permutation test = 0.116).
Subgroup analysis of ratio of n-3/n-6 PUFA for highest
quantile vs. lowest
Metaregression and subgroup analysis was performed to
explore the probable source of heterogeneity (Table 2).Although the association of increased ratio of n-3/n-6
with decreased risk of BC among 98862 participants
from 2 Asian studies was more evident than that
among 116,147 participants from 4 USA studies
(pooled RR = 0.88; 95% CI: 0.80, 0.97; I2 = 0.00%)
and 59,125 participants form 5 European studies
(pooled RR = 1.00; 95% CI: 0.84, 1.18; I2 = 8.90%),
results of metaregression did not show a significant
difference between the three populations. When stra-
tified by the adjustment for potential confounders,
metaregression did not show a significant difference
between estimates adjusted and those not adjusted for
specific covariates.
Figure 4 Summarized dose–response association between dietary ratio of n-3/n-6 PUFAs and risk of breast cancer. Adjusted RRs from
each exposure quantile of dietary ratio of n-3/n-6 PUFAs in included individual studies were represented by the gray diamonds, and correspon-
ding intervals (CIs) were represented by the lightgray trendline. The dash line indicated that dose–response linear trend (Ptrend = 0.012) between
dietary ratio of n-3/n-6 PUFAs and risk of breast cancer by use of variance-weighted least squares regression of fixed effect model; the black curve
indicated nonlinear (curvilinear) trend (Ptrend = 0.018) by use of restricted cubic splines functional model with three knots at percentiles 25%, 50%,
and 75% of the distribution.
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http://www.biomedcentral.com/1471-2407/14/105When separately analyzed by exposure assessment, we
found a significantly negative association between BC
risk and n-3/n-6 ratio in diet from 5 prospective cohort
and 1 nested case–control studies, involving 7,385 BC
invents and 271,357 participants (pooled RR = 0.92;
95% CI: 0.84, 1.00), whereas no significant association
was found between BC risk and serum PL biomarker
from 5 prospective nested case–control studies, involv-
ing 946 BC cases and 1832 controls (pooled RR = 0.86;
95% CI: 0.63, 1.20). However, there was no apparent
difference between studies using diet ratio of n-3/n-6 as
exposure and those using serum biomarker of n-3/n-6
as exposure with metaregression (P for metaregression =
0.870; P for a permutation test = 0.990).Sensitivity analysis and publication bias
Finally, we conducted sensitivity analysis and publication
bias analysis (Table 3). For dietary n-3/n-6 PUFAs ratio
as exposure, sensitivity analysis indicated that exclusion
of any individual study did not substantially change the
end results. However, for serum PL biomarker, the sensi-
tivity analysis after sequentially omitting 1 study at a time
and reanalyzing the remaining data showed that there was
significantly negative association between serum PL n-3/
n-6 ratio and BC risk (pooled RR = 0.73; 95% CI: 0.51,
1.01; I2 = 0.00%) after excluding the study by Chajes [20],indicating the overall risk estimation was substantially in-
fluenced by the single study [20].
In publication bias analysis, visual inspection of Begg’s fun-
nel plot (P = 0.244) and Egger’s regression test (P = 0.138)
showed no evidence of possible publication bias. Contour-
enhanced funnel plots of random effect model showed
studies appear to be missing in areas of high statistical signifi-
cance (p < 0.05), indicating that publication bias is a less
likely cause of the funnel asymmetry (Additional file 3).
Discussion
The present study, involving 8,331 BC events from
274,135 participants, indicated that higher ratio of n-3/
n-6 PUFAs is associated with lower risk of BC, and per
1/10 increment of n-3/n-6 ratio in diet is associated with
a 6% reduction of BC risk. However, subgroup analysis
showed there was no significant relationship between
serum PL biomarker and BC risk, but the significant
difference between association of dietary n-3/n-6 ratio
and serum PL with BC risk was not observed with
metaregression (P for metaregression = 0.87; P for a per-
mutation test = 0.99). Fatty acid profile in serum phos-
pholipids may be an untypical representative of sensitive
biomarkers indicating post-absorptive amounts and
change at the target tissue, which did not provide the
same information as the dietary questionnaire tools.
Therefore, the strength of the relationship between the
Table 2 Subgroup analysis of intake n-3/n-6 PUFAs ratio for highest quantile vs. lowest




Overall analysis 11 0.90 (0.82, 0.99) 11.40% Low 0.33
Study design 0.53 0.60
PC 5 0.92 (0.84, 1.00) 7.70% Low 0.37
NCC 6 0.82 (0.62, 1.08) 20.60% Low 0.27
Nations 0.07 0.12
Europe 5 1.00 (0.84, 1.18) 8.90% Low 0.36
USA 4 0.88 (0.80, 0.97) 0.00% Low 0.95
Asia 2 0.77 (0.59, 1.00) 0.00% Low 0.42
Menopausal status 0.18 0.26
Pre- 2 0.80 (0.43,1.48) 0.00% Low 0.42
Post- 5 0.85 (0.75.0.97) 0.00% Low 0.33
Combined 5 0.96 (0.80, 1.14) 23.30% Low 0.27
Exposure assessment 0.87 0.99
Serum PL biomarker 5 0.86 (0.63, 1.20) 21.50% Low 0.27
Diet 6 0.90 (0.82, 0.99) 17.30% Low 0.30
Follow-up duration 0.11 0.08
≤ Average value 6 0.77 (0.46, 0.94) 0.00% Low 0.77
> Average value 5 0.94 (0.83, 1.06) 19.50% Low 0.21
Covariates adjusted
BMI 0.24 0.36
Yes 8 0.91 (0.83, 1.00) 9.90% Low 0.35
No 3 0.65 (0.39,1.09) 0.00% Low 0.38
Age of fist childbirth 0.09 0.07
Yes 7 0.87 (0.79, 0.94) 0.00% Low 0.56
No 4 1.01 (0.70, 1.12) 0.00% Low 0.54
Age at menarche 0.51 0.54
Yes 6 0.92 (0.85, 0.99) 0.00% Low 0.51
No 5 0.80 (0.58,1.11) 33.60% Moderate 0.18
Parity 0.11 0.08
Yes 5 0.94 (0.85, 1.04) 15.90% Low 0.31
No 6 0.77 (0.63, 0.94) 0.00% Low 0.68
Reproductive variables 0.65 0.76
Yes 4 0.89 (0.81, 0.98) 0.00% Low 0.73
No 7 0.89 (0.74, 1.07) 33.70% Moderate 0.16
Family history of BC 0.30 0.30
Yes 8 0.91 (0.81, 1.02) 31.30% Moderate 0.18
No 3 0.76 (0.56,1.04) 0.00% Low 0.83
Hormone user 0.75 0.90
Yes 9 0.89 (0.80, 1.00) 24.50% Low 0.22
No 2 0.82 (0.50, 1.35) 0.00% Low 0.57
Alcohol intake 0.32 0.32
Yes 9 0.91 (0.82, 1.00) 0.00% Low 0.26
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Table 2 Subgroup analysis of intake n-3/n-6 PUFAs ratio for highest quantile vs. lowest (Continued)
No 2 0.72 (0.47, 1.10) 20.60% Low 0.51
Smoking 0.23 0.28
Yes 4 0.94 (0.86, 1.02) 0.00% Low 0.40
No 7 0.83 (0.70, 0.98) 8.20% Low 0.37
Age 0.78 0.99
Yes 6 0.92 (0.82, 1.02) 0.00% Low 0.45
No 5 0.86 (0.68, 1.10) 34.00% Moderate 0.18
Educational status 0.16 0.14
Yes 5 0.87 (0.80, 0.96) 0.00% Low 0.59
No 6 0.96 (0.79, 1.17) 14.70% Low 0.32
Total energy intake 0.16 0.16
Yes 5 0.87 (0.80, 0.96) 0.00% Low 0.59
No 6 0.96 (0.79, 1.17) 14.70% Low 0.32
Physical activity 0.20 0.20
Yes 3 0.81 (0.67, 0.97) 0.00% Low 0.90
No 8 0.92 (0.81, 1.05) 21.50% Low 0.25
Other drugs or nutrients intake 0.20 0.24
Yes 3 0.81 (0.67, 0.97) 0.00% Low 0.90
No 8 0.92 (0.81, 1.05) 21.50% Low 0.25
aP: P value for heterogeneity within subgroup.
bP: P value for heterogeneity between subgroups with a meta-regression analysis.
cP: adjusted P value for heterogeneity between subgroups with a permutation test.
N = number of studies.
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http://www.biomedcentral.com/1471-2407/14/105ratio in serum PL and BC risk might be lower compared
with the relationship between the ratio in diet and the
risk of BC.
Although the was no significant difference between
most subgroups with metaregression, study heterogen-
eity (I2 = 21.00%) in this meta-analysis indicated the sub-
total variation was attributable to between individual
studies. There are some possible reasons for explaining
the potential heterogeneity in present study. Firstly, the
heterogeneity from geographic regions could be partially
explained by different dietary patterns. The n-3/n-6 ratio
in Japanese diet is about 1 to 4, whereas that in western
diet (USA and Europe) is about 1 to 15–20 [37]. Imbal-
ance of n-3/n-6 PUFAs ratio in diet across different
countries is the consequence of excessive n-6 PUFAs
consumption largely from corn, sunflower or safflower
oils in the Western diet, but higher n-3 PUFAs intake
largely from marine foods in the Asian diet, particularly
in the Japanese population, which partially explains the
inconsistency between Asia and Western studies in this
meta-analysis. Subsequently, lower n-3/n-6 ratio in the
diet will lead to lower ratio of n-3/n-6 PUFAs in serum
PL. One randomized clinical trial showed that plasma
n-3/n-6 ratio significantly increased among subjects after
lovaza intervention (a prescription-strength pill, 4 g/day,
EPA +DHA = 3.36 g, duration for 2 years) comparedwith subjects without intervention [38]. In vivo, AA
(20:4n-6, arachidonic acid) and EPA (20:5n-3, eicosa-
pentaenoic acid) can simultaneously compete for the
same cyclooxygenases (COX) and lipoxygenases (LOX)
metabolism pathways, leading to the production of n-6
family derived 2-series PG and 4-series LT with promot-
ing tumor growth effects [39,40], and n-3 family derived
3-series PG and 5-series LT with suppressive effects
[41,42]. Thus, the higher ratio of n-3/n-6 PUFA entering
the cellular pool from dietary sources could be involved
in BC carcinogenesis by changing the balance of tissue
eicosanoids. Finally, there is evidence that change of
estrogen metabolism is probably involved in mam-
mary carcinogenesis among post-menopausal females
[43]. EPA/AA ratio present in cell membrane lipids
could influence the balance of prostaglandin E3 (PGE3)/
prostaglandin E2 (PGE2) to inactivate the activity of
adipose aromatase P 450 which catalyzes the conversion
of 19-carbon steroids to estrogens, and thus reduce
estrogen-stimulated cell growth action [44,45].
This meta-analysis had several strengths. Firstly, the
quantitative assessment was based on data from pro-
spective cohort studies. This minimizes the possibility
that overall analysis will be influenced due to recall bias,
which could be of more common concern in retrospect-
ive case–control studies. Also, we had higher statistical
Table 3 Sensitivity analysis for the relationship between intake n-3/n-6 PUFAs ratio and breast cancer risk
Sensitivity analysis Diet ratio of n-3/n-6 Serum PL ratio of n-3/n-6 Intake ratio of n-3/n-6
N Pooled RR
(95% CI)
Heterogeneity N Pooled RR
(95% CI)
Heterogeneity N Pooled RR
(95% CI)
Heterogeneity
I2 Degree P I2 Degree P I2 Degree P
Exclusion of studies with
potential selection bias [20,32]
5 0.87 (0.80, 0.96) 0.00% (Low) 0.5s9 4 0.73 (0.51, 1.01) 0.00% (Low) 0.67 9 0.86 (0.79, 0.94) 0.00% (Low) 0.72
Exclusion of studies without
covariates adjusted [18]
6 0.90 (0.82, 0.99) 17.30% (Low) 0.30 4 0.82 (0.56, 1.22) 36.50% (Low) 0.17 10 0.89 (0.81, 0.99) 19.10% (Low) 0.26
Contour-enhanced funnel plots
of fixed effect model
6 0.91 (0.84, 0.98) 17.30% (Low) 0.30 5 0.90 (0.68, 1.19) 21.50% (Low) 0.27 11 0.91 (0.84, 0.98) 11.40% (Low) 0.33
Contour-enhanced funnel plots
of random effect model
6 0.90 (0.82, 0.99) 17.30% (Low) 0.30 5 0.87 (0.63, 1.20) 21.50% (Low) 0.27 11 0.90 (0.82, 0.98) 11.40% (Low) 0.33

















Yang et al. BMC Cancer 2014, 14:105 Page 12 of 14
http://www.biomedcentral.com/1471-2407/14/105power to estimate the relationship between intake ratio
of n-3/n-6 PUFA and risk of BC by analyzing summary
data from 274,135 participants in 11 prospective studies.
Subsequently, serum PL as a biomarker directly reflect-
ing intake ratio of n-3/n-6 fatty acids has the advantage
of providing more objective ratio of n-3/n-6 PUFA
in vivo, independent of subjective recall bias and prob-
able measurable errors owing to dietary questionnaire
tools used. Finally, more than 50% of the studies were
high quality studies (NOS stars ≥ 8), and exclusion of
any individual study did not significantly change the
negative relationship between intake ratio of n-3/n-6
PUFAs and BC risk. Although publication bias could be
of concern because small studies with null results tend
not to be published, there was no evidence of potential
publication bias in the present meta-analysis.
Meta-analyses of observational studies are susceptible
to methodological and confounding biases inherent in
the original studies. Therefore, there are also several
limitations considered in our study. Firstly, although
prospective studies are more superior to retrospective
case–control studies with regards to elucidating causal re-
lationships, selection bias from study populations might
be still unavoidable. Volunteers recruited from occupa-
tional exposure populations (e.g., teacher, workers and
nurse) might not be an unbiased representative of study
population. Subsequently, although the fatty acid profile in
serum PL, implying absorption and circulation transporta-
tion mechanisms, reflects acute dietary intakes over the
past few days, it may be a untypical representation of sen-
sitive biomarkers indicating post-absorptive amounts and
change at the target tissue. Moreover, any measurement
error and resulting misclassification would most likely lead
to an attenuation of the true association. Intake of fatty
acids was evaluated using dietary questionnaire tools,
which could potentially have measurable errors, due to in-
accurate fatty acids database and diet reporting bias. Simi-
larly, fatty acids in serum PL,, especially long chain
PUFAs, are probably undergoing change during the long
follow-up time and storage time [46], due to double bonds
being easily oxidized. Consequently, potential measure-
ment bias might lead to underestimation or overesti-
mation of risk of BC [47]. Although only original studies
with adjusting for at least three covariates were included
in the present study, the possibility of altering summary
results from residual confounding factors still cannot be
excluded. Data extraction and analyses were not blinded
to the authors and publication agencies, and the references
screening and data extraction were conducted independ-
ently and in duplicate by 2 investigators, therefore data se-
lection bias was unlikely. Although reporting bias might
be present in our study, due to English language bias from
exclusion of non-English language articles, our eligible
studies covered a wide range of non-English countries,such as countries across Europe and Asia, which partially
eliminated the possible effects of report bias on overall risk
estimates. Finally, the limited numbers of studies included
in each subgroup might diminish the statistical power to
detect the association between ratio of n-3/n-6 PUFA and
BC risk. Although we separately made a stratified analysis
for association of serum PL ratio with BC risk and dose–
response trend, it is difficult to find firm evidences among
study populations within subgroup analysis, particular
among USA females (P for metaregression = 0.103; P for a
permutation test = 0.100).
The present meta-analysis has also important medical
implications of balanced n-3/n-6 fatty acid intake ratio for
BC prevention, clinical diagnosis and treatment. Firstly, al-
though many sensitive tumor biomarkers were used for
the clinical diagnosis of BC, several potential limitations
were still unavoidable. In addition, the BC inflammatory
microenvironment plays a major role in growth, invasive-
ness and resistance to therapy. However, modulation ratio
of n-3/n-6 fatty acids in food, as a potent inducer of meta-
bolic responses, could provide an effective means to alter
ratio of n-3/n-6 fatty acid in tumor tissue and thereby pos-
sibly affect tumor growth, by sensitizing cancer cells to
chemotherapy and increasing resistance of normal cells to
the toxic effects. Finally, diet intervention could represent
a clinically relevant adjuvant therapy in patients with BC,
based on the general tenet of clinical nutrition.
Conclusions
In summary, findings from this meta-analysis of prospective
studies provide a conclusive evidence to support increase
intake ratio of n-3/n-6 PUFAs for BC prevention among
study females. Quantitative conclusions from the present
study showed that per 1/10 increment of n-3/n-6 ratio in
diet, there was a 6% reduction of BC risk among study pop-
ulations (USA, Europe and Asia). This important evidence
highlights the need to promote nutritional education pro-
grams, stressing the need to increase the consumption of
food rich in n-3 PUFAs (marine foods), decrease the con-
sumption of food rich in n-6 PUFAs (vegetable oils and
processed foods), to ultimately improve intake ratio of n-3/
n-6 PUFAs. However, no conclusive evidence from USA
populations can be obtained and this needs to be,further
confirmed by prospective population-based study on tissue
biomarker of n-3/n-6 PUFAs ratio, and larger randomized
controlled trials are required to determine whether higher
intake ratio of n-3/n-6 PUFAs will have beneficial effects on
BC risk, or improve the prognosis of patients with BC.
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